{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T03:30:35Z","timestamp":1790134235000,"version":"4.0.1"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T00:00:00Z","timestamp":1748217600000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 HL137355"],"award-info":[{"award-number":["1R01 HL137355"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 HL107110"],"award-info":[{"award-number":["1R01 HL107110"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 HL134558"],"award-info":[{"award-number":["1R01 HL134558"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5R01 CA136387"],"award-info":[{"award-number":["5R01 CA136387"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5UM1 HL113460"],"award-info":[{"award-number":["5UM1 HL113460"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>There is limited long-term clinical outcome data supporting the use of cell-based therapy to treat heart failure. The HYPERION study (NCT03071835) followed long-term outcomes of patients with ischemic cardiomyopathy (ICM) and non-ischemic cardiomyopathy (NIDCM) who received mesenchymal stromal cells (MSC). We hypothesized that improved cardiac parameters predict longer event-free survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a Kaplan-Meier analysis to examine event-free survival as the primary outcome. Time-to-event information was captured from all eligible participants. Endpoint events were defined as death (all-cause), Left Ventricular Assist Device (LVAD) placement, or Heart Transplant. Subjects were categorized based on increase in Left Ventricular Ejection Fraction (LVEF) or decrease in Left Ventricular End Diastolic Volume (LVEDV) for comparisons within disease etiologies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 134 men and 21 women, with mean age 60.0\u2005\u00b1\u200511.0 years. There were 121 (78%) with ICM and 34 (22%) with NIDCM. By the end of long-term follow-up (~13 years), 38 (24.5%) subjects had deceased, 5 (3.2%) received LVAD, and 8 (5.2%) underwent heart transplantation. Post-therapy increase of \u22655% LVEF was associated with longer event-free survival in NIDCM (HR:0.31; 95%CI, 0.11,0.86; P\u2005=\u2005.025), but not ICM (HR:1.14; 95%CI, 0.47,2.72; P\u2005=\u2005.776). Conversely, reduction in left ventricular end-diastolic volume (LVEDV) was associated with longer event-free survival in ICM (HR:0.16; 95%CI, 0.05, 0.55; P\u2005=\u2005.008) but not NIDCM (HR:0.35; 95%CI, 0.1,1.2; P\u2005=\u2005.098). ICM improvers had LVEDV of 225.7\u2005\u00b1\u200595.9\u00a0mL at baseline and 209.0\u2005\u00b1\u2005100.6\u00a0mL by year 5 (P\u2005=\u2005.046). NIDCM improvers had LVEF of 27.2\u2005\u00b1\u20058.9% at baseline and 36.1\u2005\u00b1\u200511.6% by year 5 (P\u2005=\u2005.018).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this long-term observational cohort analysis, improvement of LVEF and\/or reduction in LVEDV was associated with survival benefits among subjects with NIDCM and ICM, respectively. In both etiologies the respective improvements are sustained for up to 5 years, providing evidence that cell-based therapy may be a promising and durable treatment option for patients with heart failure.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/stcltm\/szaf010","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:34:45Z","timestamp":1748273685000},"source":"Crossref","is-referenced-by-count":3,"title":["Long term event-free survival following cell-based therapy in patients with cardiomyopathy: the HYPERION observational cohort"],"prefix":"10.1093","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0494-3869","authenticated-orcid":false,"given":"Russell G","family":"Saltzman","sequence":"first","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Sundin","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]},{"name":"Loma Linda University Medical Center , Loma Linda, CA 92354 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina V","family":"Caceres","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo A","family":"Tovar","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Maria","family":"Garzon","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria A","family":"Cabreja","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossein","family":"Shayestehyekta","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Soto","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dushyantha","family":"Jayaweera","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Khan","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivonne H","family":"Schulman","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]},{"name":"Division of Kidney, Urologic, and Hematologic Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health , Bethesda, MD 20817 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul D","family":"Mitrani","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]},{"name":"Division of Cardiology, Miller School of Medicine, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7751-5032","authenticated-orcid":false,"given":"Joshua M","family":"Hare","sequence":"additional","affiliation":[{"name":"Leonard M. Miller School of Medicine, Interdisciplinary Stem Cell Institute, University of Miami , Miami, FL 33136 ,","place":["United States"]},{"name":"Division of Cardiology, Miller School of Medicine, University of Miami , Miami, FL 33136 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,26]]},"reference":[{"key":"2025052611344210800_CIT0001","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/jama.2013.282909","article-title":"Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy","volume":"311","author":"Heldman","year":"2014","journal-title":"JAMA"},{"key":"2025052611344210800_CIT0002","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1001\/jama.2012.25321","article-title":"Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial","volume":"308","author":"Hare","year":"2012","journal-title":"JAMA"},{"key":"2025052611344210800_CIT0003","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/CIRCRESAHA.117.311827","article-title":"Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT Study)","volume":"121","author":"Florea","year":"2017","journal-title":"Circ Res"},{"key":"2025052611344210800_CIT0004","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jacc.2016.11.009","article-title":"Randomized comparison of allogeneic versus autologous mesenchymal stem cells for nonischemic dilated cardiomyopathy: POSEIDON-DCM trial","volume":"69","author":"Hare","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025052611344210800_CIT0005","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ejhf.2178","article-title":"A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial","volume":"23","author":"Bolli","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2025052611344210800_CIT0006","doi-asserted-by":"publisher","first-page":"2","DOI":"10.5966\/sctm.2013-0104","article-title":"Moving beyond surrogate endpoints in cell therapy trials for heart disease","volume":"3","author":"Malliaras","year":"2014","journal-title":"Stem Cells Transl Med."},{"key":"2025052611344210800_CIT0007","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1161\/CIRCRESAHA.118.311217","article-title":"Clinical studies of cell therapy in cardiovascular medicine","volume":"123","author":"Banerjee","year":"2018","journal-title":"Circ Res"},{"key":"2025052611344210800_CIT0008","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1093\/cvr\/cvab135","article-title":"Cell therapy in patients with heart failure: a comprehensive review and emerging concepts","volume":"118","author":"Bolli","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2025052611344210800_CIT0009","first-page":"16","article-title":"The sad plight of cell therapy for heart failure: causes and consequences","volume":"2","author":"Bolli","year":"2022","journal-title":"J Cardiovas Aging"},{"key":"2025052611344210800_CIT0010","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1161\/CIRCHEARTFAILURE.109.855023","article-title":"A pilot trial to assess potential effects of selective intracoronary bone marrow\u2013derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy","volume":"2","author":"Fischer-Rasokat","year":"2009","journal-title":"Circulation: Heart Failure."},{"key":"2025052611344210800_CIT0011","doi-asserted-by":"publisher","first-page":"3061","DOI":"10.1093\/eurheartj\/ehv390","article-title":"Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial","volume":"36","author":"Hamshere","year":"2015","journal-title":"Eur Heart J."},{"key":"2025052611344210800_CIT0012","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s10741-023-10351-0","article-title":"Stem cell-based therapies for heart failure management: a narrative review of current evidence and future perspectives","volume":"29","author":"Olatunji","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2025052611344210800_CIT0013","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/j.jcyt.2024.07.004","article-title":"20 years of treating ischemic cardiomyopathy with mesenchymal stromal cells: a meta-analysis and systematic review","volume":"26","author":"Seyihoglu","year":"2024","journal-title":"Cytotherapy"},{"key":"2025052611344210800_CIT0014","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s13287-024-03891-1","article-title":"Mid- to long-term efficacy and safety of stem cell therapy for acute myocardial infarction: a systematic review and meta-analysis","volume":"15","author":"Lee","year":"2024","journal-title":"Stem Cell Res Ther."},{"key":"2025052611344210800_CIT0015","article-title":"Trials and tribulations of cell therapy for heart failure: an update on ongoing trials","author":"Zhang","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"2025052611344210800_CIT0016","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1161\/CIRCRESAHA.116.309717","article-title":"Intravenous allogeneic mesenchymal stem cells for nonischemic cardiomyopathy","volume":"120","author":"Butler","year":"2017","journal-title":"Circ Res"},{"key":"2025052611344210800_CIT0017","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.hfc.2021.05.007","article-title":"Left ventricular assist device: indication, timing, and management","volume":"17","author":"Frigerio","year":"2021","journal-title":"Heart Fail Clin"},{"key":"2025052611344210800_CIT0018","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1590\/S1679-45082015RW3154","article-title":"Heart transplantation: review","volume":"13","author":"Mangini","year":"2015","journal-title":"Einstein (Sao Paulo)"},{"key":"2025052611344210800_CIT0019","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","article-title":"Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials","volume":"7","author":"Lalu","year":"2012","journal-title":"PLoS One"},{"key":"2025052611344210800_CIT0020","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ahj.2010.09.025","article-title":"CD34+ cell infusion after ST elevation myocardial infarction is associated with improved perfusion and is dose dependent","volume":"161","author":"Quyyumi","year":"2011","journal-title":"Am Heart J"},{"key":"2025052611344210800_CIT0021","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1093\/eurheartj\/ehv136","article-title":"Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial)","volume":"36","author":"Mathiasen","year":"2015","journal-title":"Eur Heart J"},{"key":"2025052611344210800_CIT0022","doi-asserted-by":"publisher","first-page":"e011284","DOI":"10.1161\/CIRCINTERVENTIONS.121.011284","article-title":"Change in left ventricular ejection fraction with coronary artery revascularization and subsequent risk for adverse cardiovascular outcomes","volume":"15","author":"Velagaleti","year":"2022","journal-title":"Circ Cardiovasc Interv."},{"key":"2025052611344210800_CIT0023","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamacardio.2018.3957","article-title":"Estimated 5-year number needed to treat to prevent cardiovascular death or heart failure hospitalization with angiotensin receptor-Neprilysin inhibition vs standard therapy for patients with heart failure with reduced ejection fraction: an analysis of data from the PARADIGM-HF trial","volume":"3","author":"Srivastava","year":"2018","journal-title":"JAMA Cardiol."},{"key":"2025052611344210800_CIT0024","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jacc.2022.11.061","article-title":"Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure","volume":"81","author":"Perin","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2025052611344210800_CIT0025","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.ebiom.2019.09.043","article-title":"Genetic determinants of responsiveness to mesenchymal stem cell injections in non-ischemic dilated cardiomyopathy","volume":"48","author":"Rieger","year":"2019","journal-title":"EBioMed."},{"key":"2025052611344210800_CIT0026","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.ebiom.2015.03.020","article-title":"Allogeneic mesenchymal stem cells restore endothelial function in heart failure by stimulating endothelial progenitor cells","volume":"2","author":"Premer","year":"2015","journal-title":"EBioMed."},{"key":"2025052611344210800_CIT0027","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1038\/s41598-024-53776-9","article-title":"Follow-up of intramyocardial bone marrow mononuclear cell transplantation beyond 10 years","volume":"14","author":"Mulari","year":"2024","journal-title":"Sci Rep"},{"key":"2025052611344210800_CIT0028","doi-asserted-by":"publisher","first-page":"100702","DOI":"10.1016\/j.conctc.2021.100702","article-title":"Demographic representation in clinical trials for cell-based therapy","volume":"21","author":"Saltzman","year":"2021","journal-title":"Contemp Clin Trials Commun."}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/14\/5\/szaf010\/63356149\/szaf010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/14\/5\/szaf010\/63356149\/szaf010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T15:34:46Z","timestamp":1748273686000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szaf010\/8149225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szaf010","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"szaf010"}}